Eric Linn
- Oncology top 0.5%
- Cancer survivorship and care 2
-
- Childhood Cancer Survivors' Quality of Life 1
- Otorhinolaryngology top 1%
-
- Health Systems, Economic Evaluations, Quality of Life 2
-
- Pharmacovigilance and Adverse Drug Reactions 1
-
- Erythropoietin and Anemia Treatment 1
-
- Diabetes and associated disorders 1
-
- Chronic Disease Management Strategies 1
-
- Drug-Induced Adverse Reactions 1
- Co-authors
- David S. TulskyM SilbermanS B YellenDavid CellaAmy E. BonomiShawn E. BeardenRobin Looft‐WilsonHeather Morrison
- Journals
- Journal of Clinical Oncology (2 papers)American Journal of Health-System Pharmacy (2 papers)Journal of the American Pharmacists Association (1 paper)
- Partner nations
- United States
In The Last Decade
Eric Linn
5 papers receiving 4.6k citations
Hit Papers
Peers
Comparison fields: 5 of 119
- Oncology 3.0k
- Pediatrics, Perinatology and Child Health 1.3k
- Otorhinolaryngology 266
- Public Health, Environmental and Occupational Health 994
- Pulmonary and Respiratory Medicine 1.1k
Countries citing papers authored by Eric Linn
This map shows the geographic impact of Eric Linn's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eric Linn with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eric Linn more than expected).
Fields of papers citing papers by Eric Linn
This network shows the impact of papers produced by Eric Linn. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eric Linn. The network helps show where Eric Linn may publish in the future.
Co-authorship network
The 10 scholars most cited alongside Eric Linn, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 1 | |
| 2 | 2024 | 0 | |
| 3 | 2023 | 18 | |
| 4 | 2023 | 2 | |
| 5 | 2007 | 14 | |
| 6 | The Functional Assessment of Cancer Therapy scale: development and validation of the general measure.breakdown → | 1993 | 4722 |
About Eric Linn
Eric Linn is a scholar working on Toxicology, Nephrology, Emergency Medicine, Hematology and Oncology, having authored 6 papers that have together received 4.8k indexed citations. Recurring topics across this work include Health Systems, Economic Evaluations, Quality of Life (2 papers), Cancer survivorship and care (2 papers), Pharmacovigilance and Adverse Drug Reactions (1 paper), Erythropoietin and Anemia Treatment (1 paper), Diabetes and associated disorders (1 paper), Chronic Disease Management Strategies (1 paper), Childhood Cancer Survivors' Quality of Life (1 paper) and Drug-Induced Adverse Reactions (1 paper). The work is most often cited by research in Oncology (3.0k citations), Pediatrics, Perinatology and Child Health (1.3k citations), Otorhinolaryngology (266 citations), Public Health, Environmental and Occupational Health (994 citations) and Pulmonary and Respiratory Medicine (1.1k citations). Eric Linn has collaborated with scholars based in United States. Frequent co-authors include David S. Tulsky, M Silberman, S B Yellen, David Cella, Amy E. Bonomi, Shawn E. Bearden, Robin Looft‐Wilson, Heather Morrison, Stephen Gilbert and John W. Perry. Their work appears in journals such as Journal of Clinical Oncology, American Journal of Health-System Pharmacy, Journal of the American Pharmacists Association and American Journal of Physiology-Regulatory, Integrative and Comparative Physiology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.